Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
Stocks Close Higher After Positive Retail Data
Veronica Willis, investment strategy analyst with Wells Fargo Investment Institute, joined Cheddar News to discuss Wednesday's trading session following better-than-expected retail sales and what's on tap for the markets this year.
Load More